CervoMed Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $4.0M | $9.7M | $7.1M | $0 | $71.7K | $374.5K | $570.5K | $40.2K |
| Cost of Revenue | — | — | — | — | $0 | $235.8K | $2.3M | $210.4K |
| Gross Profit | — | — | — | — | $71.7K | $138.7K | $-1.7M | $-170.2K |
| Gross Margin | — | — | — | — | 100.0% | 37.0% | -304.7% | -423.5% |
| Operating Expenses | ||||||||
| Research & Development | $21.8M | $18.8M | $8.4M | $1.3M | $342.9K | — | — | — |
| SG&A Expense | $10.5M | $9.2M | $6.5M | $2.1M | $7.3M | $4.6M | $6.7M | $2.2M |
| Operating Income | $-28.3M | $-18.2M | $-7.8M | $-3.5M | $-12.8M | $-11.8M | $-16.4M | $-7.6M |
| Operating Margin | -706.2% | -187.2% | -109.3% | — | -17,855.5% | -3,148.3% | -2,879.9% | -19,002.6% |
| Interest Expense | — | — | $0 | $587 | $126.5K | $-167.9K | $30.5K | $81.4K |
| Pretax Income | — | — | — | $-15.6M | $-3.0M | — | — | — |
| Income Tax Expense | $0 | — | — | $0 | $0 | $0 | — | — |
| Net Income | $-27.0M | $-16.3M | $-2.2M | $-5.8M | $-2.5M | $-6.9M | $-22.6M | $-8.4M |
| Net Margin | -673.1% | -167.3% | -30.4% | — | -3,429.7% | -1,833.9% | -3,967.9% | -20,925.1% |
| EPS (Basic) | $-2.98 | $-2.02 | $-0.27 | $-0.75 | $0.00 | $-0.01 | $0.00 | $0.00 |
| EPS (Diluted) | — | — | — | $135,926.07 | $0.00 | $-0.01 | $0.00 | $0.00 |
| Shares Outstanding (Basic) | 9.0M | 8.1M | 8.0M | 7.8M | — | — | — | — |
| Shares Outstanding (Diluted) | 9.0M | 8.1M | 8.0M | 7.8M | 794.0M | 673.2M | 60.61B | — |
| Dividends Per Share | — | — | — | — | — | — | — | — |